Top of the Class

New certificate course trains a ready workforce as biotech companies in Pearland take off

There's a much greater need for biotech workers. Photo courtesy of Lonza

Biotech companies in Pearland are thriving, with big names such as Lonza, Millar Inc. Inc., and Abbott all experiencing tremendous growth in recent years.

The only challenge to this success is the increased demand for a faster workforce pipeline. Fortunately, the Pearland Economic Development Corporation (PEDC) has a solution.

PEDC has partnered with Alvin Community College (ACC) and Lonza to create a two-level Biotechnology Certificate Course designed to address the need for a better-equipped entry-level workforce.

This initiative offers two options to quickly train individuals for employment in the biotech field: Level 1, a six-week commitment for Biotech: Material Handler; and Level 2, a twelve-week commitment for Biotech: Lab Technician. Each level consists of 64 contact hours, with lectures delivered online and labs and assessments conducted on-site.

Alvin Community College is offering this course, which commenced on August 21, under its Continued Education and Workforce Development (CEWD) department. This department provides programs that incorporate current and new technical courses, training partnerships with businesses and industries, and other opportunities for individuals to acquire and upgrade skills or pursue personal enrichment.

Before this initiative, the region's two- or four-year programs were only graduating a dozen or so individuals. Early discussions focused on how to expedite workforce development through a local community college's certificate program. Alvin Community College was prepared to respond to the local workforce's needs.

PEDC played a pivotal role in establishing an advisory committee comprised of industry partners responsible for vetting the Biotechnology Certificate Course curriculum. Industry partners included the University of Houston Clear Lake (UHCL) at Pearland, Lonza, Millar Inc., Merit Medical, and the nonprofit organization BioHouston.

These partners are invaluable as plans continue to expand these certification programs.

Given the ever-increasing demand for a biotechnology workforce in the Pearland area, the future wish list includes expanding the certification program to other education partners.

For more information about the Biotechnology Certificate Program at Alvin Community College, visit this link.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted